Is The 21st Century Cures Act Good Or Bad For The Biopharmaceutical Industry?

http://ift.tt/1R6Uwx1
The industry might benefit in the short-term by the more rapid approval of experimental medicines. However, the downstream consequences may outweigh any immediate benefits.

Vía Forbes Real Time http://onforb.es/1QEF2ya